Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Valion Bio, Inc.
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
September 30, 2026
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23, 2026
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22, 2026
Valion Bio Announces Changes to Management and Board of Directors
September 1, 2026
Ukraine’s Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
August 13, 2026
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
August 12, 2026